Assessment of Peripheral Endothelial Function in Idiopathic Pulmonary Fibrosis (Endoth-FPI)
Primary Purpose
Pulmonary Fibrosis
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
endothelial function
Sponsored by
About this trial
This is an interventional basic science trial for Pulmonary Fibrosis focused on measuring endothelial function, idiopathic pulmonary fibrosis
Eligibility Criteria
Inclusion Criteria:
- IPF according to ATS/ERS 2011's criteria
- Stable IPF (no reduction of FVC or DLCO of more than 10% and 15% respectively)
Exclusion Criteria:
- Patients with a significant disease other than IPF. A significant disease is defined as a disease which, in the opinion of the investigator, may influence the results of the trial.
- Pregnant or nursing women.
- Non-pulmonary fibrosis
- treatment by pulmonary vasodilators that cannot be stopped for 24 hours for the assessment of endothelial function
Sites / Locations
- Hopital Europeen Georges Pompidou, dpt of pneumology
- Hopital Foch
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Pulmonary idiopathic fibrosis
Arm Description
Patients with pulmonary idiopathic fibrosis according to ATS/ERS 2011's criteria
Outcomes
Primary Outcome Measures
measure of reactive hyperemia-peripheral artery tone index
Secondary Outcome Measures
endothelial function
measure of reactive hyperemia-peripheral artery tone index
measure of reactive hyperemia-peripheral artery tone index
measure of reactive hyperemia-peripheral artery tone index at IPF exacerbation or PAHT's occurence
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02594059
Brief Title
Assessment of Peripheral Endothelial Function in Idiopathic Pulmonary Fibrosis
Acronym
Endoth-FPI
Official Title
Assessment of Peripheral Endothelial Function in Idiopathic Pulmonary Fibrosis
Study Type
Interventional
2. Study Status
Record Verification Date
March 2021
Overall Recruitment Status
Completed
Study Start Date
December 19, 2012 (Actual)
Primary Completion Date
July 15, 2020 (Actual)
Study Completion Date
July 15, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hopital Foch
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The aim of the study is to assess the peripheral endothelial function in adult patients with idiopathic pulmonary fibrosis (IPF) and the relationship between the peripheral endothelial function and the severity of the IPF.
Detailed Description
The primary criteria is the peripheral endothelial function that will be assessed by the measure of flow-mediated dilation (reactive hyperemia-peripheral artery tone index). The pulmonary function will be assessed by the measures of the forced expiratory volume at one second (FEV1), the forced vital capacity (FVC) and the total lung capacity (TLC) and the diffusing capacity of the lung for carbon monoxide (DLCO). The dyspnea will be assessed with the New York Heart Association (NYHA) score. The exercise capacity will be assessed by the 6-min walk test. Pulmonary arterial pressure will be recorded through cardiac echography or catheterization.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pulmonary Fibrosis
Keywords
endothelial function, idiopathic pulmonary fibrosis
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
43 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Pulmonary idiopathic fibrosis
Arm Type
Experimental
Arm Description
Patients with pulmonary idiopathic fibrosis according to ATS/ERS 2011's criteria
Intervention Type
Other
Intervention Name(s)
endothelial function
Intervention Description
measure of reactive hyperemia-peripheral artery tone index
Primary Outcome Measure Information:
Title
measure of reactive hyperemia-peripheral artery tone index
Time Frame
day 1
Secondary Outcome Measure Information:
Title
endothelial function
Description
measure of reactive hyperemia-peripheral artery tone index
Time Frame
1, 2 and 3 years
Title
measure of reactive hyperemia-peripheral artery tone index
Description
measure of reactive hyperemia-peripheral artery tone index at IPF exacerbation or PAHT's occurence
Time Frame
3 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
IPF according to ATS/ERS 2011's criteria
Stable IPF (no reduction of FVC or DLCO of more than 10% and 15% respectively)
Exclusion Criteria:
Patients with a significant disease other than IPF. A significant disease is defined as a disease which, in the opinion of the investigator, may influence the results of the trial.
Pregnant or nursing women.
Non-pulmonary fibrosis
treatment by pulmonary vasodilators that cannot be stopped for 24 hours for the assessment of endothelial function
Facility Information:
Facility Name
Hopital Europeen Georges Pompidou, dpt of pneumology
City
Paris
ZIP/Postal Code
75015
Country
France
Facility Name
Hopital Foch
City
Suresnes
ZIP/Postal Code
92150
Country
France
12. IPD Sharing Statement
Learn more about this trial
Assessment of Peripheral Endothelial Function in Idiopathic Pulmonary Fibrosis
We'll reach out to this number within 24 hrs